Global Chemotherapy-Induced Neutropenia Treatment Market Size By Type (Antibiotic Therapy, Colony-Stimulating Factor Therapy), By Application (Hospitals, Ambulatory Surgical Center), By Region, And Se...

The Global Chemotherapy-Induced Neutropenia (CIN) Treatment Market was valued at USD 10.3 billion in 2023 and is projected to reach USD 18.6 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. CIN is one of the most common and serious side effects of cancer treatment, significantly increasing patients’ risk of infection and impacting chemotherapy dosing and scheduling. The market growth is primarily driven by the rising global incidence of cancer, growing awareness about CIN management, and increased adoption of granulocyte colony-stimulating factors (G-CSFs) to reduce infection risks and maintain chemotherapy intensity.

Drivers:

Rising Global Cancer Burden:

The increasing prevalence of various cancers worldwide is leading to a proportional rise in the number of patients undergoing chemotherapy. This has resulted in a higher incidence of CIN, thereby driving the demand for effective treatment solutions.

Increased Use of Chemotherapy Regimens:

With chemotherapy remaining a cornerstone in cancer treatment protocols, the usage of myelosuppressive therapies has surged. This increases the risk of neutropenia, thus fueling demand for supportive treatments such as G-CSFs.

Advancements in Biosimilars and Targeted Therapies:

The development and commercialization of biosimilar G-CSFs, offering comparable efficacy at reduced costs, have expanded access and stimulated market growth, particularly in cost-sensitive regions.

Restraints:

High Treatment Costs and Reimbursement Limitations:

Despite biosimilar penetration, the overall cost of CIN treatments—particularly pegylated G-CSFs—can be high. Inadequate reimbursement policies in certain regions pose a significant challenge to market expansion.

Adverse Effects and Complications:

Some CIN treatment drugs are associated with side effects such as bone pain, splenic rupture, and allergic reactions, which can limit their usage among sensitive patient populations.

Opportunity:

Rising Focus on Prophylactic Use in Oncology Protocols:

Proactive inclusion of CIN management in cancer care guidelines and growing oncologist preference for prophylactic G-CSF administration open lucrative growth avenues.

Expansion in Emerging Markets:

The oncology therapeutic landscape is evolving rapidly in emerging economies such as India, China, and Brazil. Growing healthcare investment and expanding cancer treatment infrastructure in these regions present strong market potential.

Market by System Type Insights:

By system type, the short-acting G-CSFs segment held the largest share in 2023. These agents, including filgrastim and its biosimilars, are widely used due to their established clinical efficacy and affordability. However, the long-acting G-CSFs segment (e.g., pegfilgrastim) is expected to register the fastest growth, driven by their dosing convenience and increasing patient compliance.

Market by End-use Insights:

In terms of end-use, the hospital pharmacy segment dominated the market in 2023. CIN treatments are predominantly administered in hospital settings, where patient monitoring is frequent. Nonetheless, the retail pharmacy and online pharmacy segments are gaining traction due to increased outpatient treatments and e-prescription services.

Market by Regional Insights:

North America led the market in 2023, driven by a high cancer incidence rate, robust healthcare infrastructure, and widespread use of G-CSFs. Asia-Pacific is projected to witness the highest growth through 2031, fueled by increasing cancer cases, rising awareness, and expanding healthcare access in countries such as China and India.

Competitive Scenario:

Leading companies operating in the global CIN treatment market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V. (Viatris), Coherus BioSciences Inc., Sandoz (a Novartis Division), Pfizer Inc., and Biocon Biologics. These firms are actively engaged in expanding their biosimilar portfolios, entering strategic alliances, and investing in R&D to improve treatment efficacy and affordability.

Scope of Work – Global Chemotherapy-Induced Neutropenia Treatment Market:

Key Market Developments:

2023: Coherus BioSciences launched its biosimilar UDENYCA ONBODY®, a pegfilgrastim on-body injector, to enhance convenience for patients undergoing chemotherapy.

2023: Teva Pharmaceuticals and BIOELECTRONICS partnered to improve distribution of biosimilar filgrastim in Eastern Europe.

2024: Amgen announced data from real-world studies supporting the efficacy and safety of Neulasta® in high-risk cancer patients.

FAQs:

1) What is the current market size of the Global Chemotherapy-Induced Neutropenia Treatment Market?

The market was valued at USD 10.3 billion in 2023.

2) What is the major growth driver of the Global Chemotherapy-Induced Neutropenia Treatment Market?

The primary driver is the rising global incidence of cancer and increased chemotherapy utilization.

3) Which is the largest region during the forecast period in the Global Chemotherapy-Induced Neutropenia Treatment Market?

North America is the largest region, attributed to high cancer prevalence and healthcare expenditure.

4) Which segment accounted for the largest market share in Global Chemotherapy-Induced Neutropenia Treatment Market?

Short-acting G-CSFs dominated the market by system type in 2023.

5) Who are the key market players in the Global Chemotherapy-Induced Neutropenia Treatment Market?

Key players include Amgen Inc., Teva Pharmaceutical Industries, Coherus BioSciences, Sandoz, Pfizer Inc., and Biocon Biologics.